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Protein–protein interactions are involved in diverse biological processes. These interactions are therefore
vital targets for drug development. However, the design of peptide modulators targeting membrane-
based protein–protein interactions is a challenging goal owing to the lack of experimentally-determined
structures and eﬃcient protocols to probe their functions. Here we employed rational peptide design
and molecular dynamics simulations to design a membrane-insertable peptide that disrupts the strong
trimeric self-association of the ﬁfth transmembrane domain (TMD5) of the oncogenic Epstein–Barr virus
(EBV) latent membrane protein-1 (LMP-1). The designed anti-TMD5 peptide formed 1 : 2 heterotrimers
with TMD5 in micelles and inhibited TMD5 oligomerization in bacterial membranes. Moreover, the
designed peptide inhibited LMP-1 homotrimerization based on NF-kB activity in EVB positive lymphoma
cells. The results indicated that the designed anti-TMD5 peptide may represent a promising starting point
for elaboration of anti-EBV therapeutics via inhibition of LMP-1 oligomerization. To the best of our
knowledge, this represents the ﬁrst example of disrupting homotrimeric transmembrane helices using
a designed peptide inhibitor.Introduction
Membrane proteins make up 30% of the human genome, and
included in this group are high priority drug targets such as the
G protein-coupled receptor (GPCR) family.1 Furthermore,
protein–protein interactions in the membrane play vital roles in
membrane protein assembly to coordinate a variety of cellular
processes.2–4 These interactions within the membrane are
therefore important potential targets for the development of
chemical probes and therapeutics.5,6 Despite this opportunity,n Institute of Applied Chemistry, Chinese
022, China. E-mail: xiaohui.wang@ciac.
hina, Sun Yat-sen University, Guangzhou,
gy of Special Wild Economic Animals,
ences, Chinese Academy of Agricultural
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iology, University of Leeds, Woodhouse
rganic Chemistry, Russian Academy of
Engineering, University of Science and
China
tion (ESI) available. See DOI:
0there are intrinsic challenges to study transmembrane domains
of membrane proteins, including the low number of
experimentally-determined structures and relatively few
methods to probe the functions of these domains compared to
their water-soluble counterparts.7–11
Epstein–Barr virus (EBV) causes a prevalent infection that
has been identied as the causative agent of a number of
cancers including Burkitt lymphoma, B-cell lymphoma, and
Hodgkin's disease.12–15 EBV infects B cells with transformation
occurring as a consequence of viral proteins constantly acti-
vating signalling cascades for cellular proliferation, diﬀerenti-
ation, and survival (Fig. 1).16 Central to this transformation
process is the viral protein, latent membrane protein-1 (LMP-1),
which constitutively activates NF-kB and other pathwaysFig. 1 Schematic of transformation of EBV infected B cells.
This journal is © The Royal Society of Chemistry 2019
Fig. 2 Computational design of anti-TMD5 based on a TMD5
homology model: (a) ribbon representation of homotrimeric TMD5
(chain A: grey, chain B: red, and chain C: blue). The key residues
Asp150 are shown in stick representation and the hydrogen bonds
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View Article Onlinethrough a direct interaction with tumor necrosis factor
receptor-associated factors (TRAFs) via LMP-1's C-terminal
domain.17–19 Furthermore, the signalling activity of LMP-1 is
contingent on the oligomerization of its six transmembrane
helix domains, specically through transmembrane domain 5
(TMD5).20 Previous studies demonstrated that TMD5 can be
trimerized by itself and polar amino acids, such as Asp150, drive
transmembrane helix association.20,21
Recently small molecule inhibitors have been discovered by
targeting LMP-1's TMD5 trimerization.21,22 Due to the large
interfaces of protein–protein interactions (PPIs), it is chal-
lenging to disrupt PPIs at the membrane and the activities of
small molecule inhibitors of TMD5 are moderate.23 Compared
to small molecule agents, peptides have much larger interacting
interfaces. Rational peptide design has been an eﬃcient and
reliable method for drugging the “undruggable” trans-
membrane domains of membrane proteins. Modulation of
transmembrane protein dimerization via peptide modulators
has been demonstrated in Toll-like receptors (TLRs),24,25 ErbB
receptors,26 and integrins.27 However, no peptide inhibitors that
target transmembrane protein trimerization have been
unveiled. Herein, an anti-TMD5 peptide was designed to target
trimeric TMD5 (Fig. 2a) of LMP-1 with better activity than TMD5
small molecule disruptors. Its ability to disrupt the assembly of
the homotrimeric TMD5 complex was conrmed and charac-
terized by biophysical and cell-based assays. The designed anti-
TMD5 peptide represents a powerful starting point from which
to further develop potent peptidomimetics for inhibiting LMP-1
signaling.between them are represented with yellow dashed lines; (b) sequence
alignment of TMD5 and variant TMD5 (anti-TMD5). The variant resi-
dues in anti-TMD5 are highlighted in red; (c) representative illustration
from an MD simulation; trimeric TMD5s (orange) are embedded in
DMPC lipid bilayer (cyan). Chloride and potassium ions are shown as
cyan and orange spheres, respectively. The simulated aqueous phase
is shown as a green box; (d) RMSF of backbone of homotrimer and
heterotrimer_1 : 2 (one anti-TMD5 and two TMD5s). The signiﬁcant
diﬀerence in motion of residues between the two coiled-coils is
highlighted by a magenta line (residues 140–143).Results and discussion
Rosetta rational peptide design
Rational protein design has been applied to design enzymes
and peptide modulators.28–31 In this study, 50 designs were rst
generated using the Rosetta molecular modelling package,32,33
and the best anti-TMD5 sequence (WWKLWYFLVWFLDLII-
LILLLWW) (Fig. 2b) was selected for further analysis based on
the RosettaDesign energy scores.34–37Molecular dynamics simulations
The heterotrimer system (named as heterotrimer_1 : 2) with
one anti-TMD5 (chain A in the trimer) and two TMD5 mono-
mers was built based on the homotrimeric TMD5 (Fig. 2c). The
stabilities of the homotrimer and heterotrimer_1 : 2 in a DMPC
membrane were validated via the root-mean-square deviation
(RMSD). As shown in Fig. S1,† the homotrimer and hetero-
trimer_1 : 2 reached a stable conformation in 10 ns. Hence the
last 90 ns of the 100 ns simulation trajectories were employed
for subsequent analyses. The backbone root-mean-square uc-
tuation (RMSF) of each transmembrane helix in the homo-
trimer and the heterotrimer_1 : 2 was calculated to unveil the
uctuation of each residue during the last 90 ns of simulation.
The RMSF values for residues 140–143 of heterotrimer_1 : 2
were smaller than those observed for the homotrimer in Fig. 2d,
indicating this region of the trimeric coiled-coil became moreThis journal is © The Royal Society of Chemistry 2019rigid aer the anti-TMD5 replaced a monomer of the
homotrimer.
One water molecule was observed to be captured by the
homotrimer in 11 ns (Fig. 3a). It has been proven that solvent
accessibility decreases the stability of transmembrane coiled-
coil trimers in lipid bilayers.38 Aer the water molecule moved
into the lumen from the bulk water, it rst localized to a deeper
site (location 1 in Fig. 3a) and coordinated with Ala146 and
Asp150 for 35 ns. Then it jumped to a more stable site (loca-
tion 2 in Fig. 3a) to interact with Ala146, Phe147 and Asp150 and
remained in this location for more than 50 ns. However, no
water molecules were found in the lumen of heterotrimer_1 : 2
because all residues observed to interact with water in the
homotrimer were varied for other residues in chain A of the
heterotrimer_1 : 2 except Asp150.
To analyse the interactions between each of the (two)
helices, the occupancy of hydrogen bonds (occupancy ¼Chem. Sci., 2019, 10, 7584–7590 | 7585
Fig. 3 Molecular dynamics simulations for trimeric interactions: (a)
water molecule locations in the homotrimer homology model. The
distance between the oxygen of the water molecule and the center of
mass of the Ca of the homotrimer homology model were calculated.
Based on the distance, the water molecule experienced three states: in
the bulk water, in location 1 and in location 2. The top view and side
view of conformations of water in two locations of homotrimeric
TMD5 (grey) are displayed, respectively, with key amino acid residues
observed to interact with the water molecule labelled (green sticks); (b
and c) hydrogen bond occupancy formed by Asp150 (b) and by all
residues (c) between each chain. The order of chains A, B and C is
displayed in Fig. 2a and (a).
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View Article Onlinenumber of hydrogen bonds/total number of frames in the
trajectory) between Asp150 of two monomers during the last
50 ns of each trajectory was counted, since one water molecule
reached its most stable location in the homotrimer homology
model aer 50 ns. As shown in Fig. 3b, Asp150 of chain B in the
homotrimer barely formed hydrogen bonds with Asp150 from
other chains because of the existence of a water molecule.
Most hydrogen bonds formed between Asp150s were from
chain A and chain C. Therefore, these observations suggest
water molecules in the lumen can screen intermolecular
interactions within trimers and decrease their stability in the
lipid bilayer. Gln139 is another key residue that forms
hydrogen bonds stabilizing the homotrimer (occupancy ¼
24.55  1.73%). It is also a vital residue to capture the water
molecule from the bulk according to the molecular dynamics
simulations. For the heterotrimer_1 : 2, hydrogen bonds
between the Asp150s were well distributed amongst each
chain because no water molecule was observed to compete
with these interactions. A more even distribution of7586 | Chem. Sci., 2019, 10, 7584–7590interactions fosters greater trimer stability in the hetero-
trimer_1 : 2. Since Gln139 in chain A of homotrimer was
varied for tryptophan in heterotrimer_1 : 2 (Fig. S2†), it cannot
form hydrogen bonds any more. Instead, Tyr143 of anti-TMD5
(chain A) interacted with Ala142 of chain B or C (Fig. S2†), and
the interactions locked the region comprising residues 140–
143, accounting for the increased rigidity observed in the
simulations (Fig. 2d). The total number of hydrogen bonds
observed between each of the two chains (Fig. 3c) follows
a similar trend to those observed for Asp150 (Fig. 3b). The
occupancy of hydrogen bonds thus indicates that the anti-
TMD5 peptide can form stronger interactions with chain B
and provide an even distribution of interactions in the heter-
otrimer_1 : 2. This may rationalize the stabilizing eﬀect on the
whole system observed for anti-TMD5 in silico, providing
a basis upon which the designed anti-TMD5 may disrupt the
lateral association of transmembrane helices of TMD5 as
a peptide inhibitor.Biophysical chemistry characterization
To validate the eﬀects of anti-TMD5 in vitro, the peptide
sequence was synthesized. Four lysine (K) residues were added
on both the N- & C-termini of anti-TMD5 to increase water
solubility, which did not aﬀect TMD5 trimerization.22 Circular
dichroism (CD) spectra of anti-TMD5 in the presence of C14
betaine (3-(N,N-dimethylmyristyl-ammonio)propanesulfonate)
micelle exhibited a typical a-helical conformation (76%) with
two minima at 208 nm and 220 nm (Fig. S3†).
To test whether anti-TMD5 could inhibit TMD5 self-
association, uorescence dequenching experiments were per-
formed. TMD5 forms a homotrimer in the presence of C14
betaine micelles, resulting in coumarin uorescence self-
quenching. Disruption of TMD5 oligomerization dequenches
the coumarin dye, leading to uorescence enhancement.21,22 As
shown in Fig. 4a, anti-TMD5 was found to eﬃciently disrupt
TMD5 self-association and reverse the coumarin uorescence
quenching. In contrast, the anti-TMD5 scrambled control
peptide, where Asp150 was kept, did not cause the coumarin
uorescence of TMD5 to increase, demonstrating the specic
interaction of anti-TMD5 with TMD5. Compared to TMD-5
disruptor NSC259242 (ref. 21) (EC50 ¼ 27.9  3.9 mM), anti-
TMD5 (EC50 ¼ 3.3  0.2 mM) showed 10-fold increase in dis-
ruptor activity.
Fluorescence resonance energy transfer (FRET) was used to
further investigate the association of anti-TMD5 with TMD5
in micelles. The titration of coumarin-tagged TMD5 as a FRET
donor, with FITC-tagged anti-TMD5 as a FRET acceptor,
resulted in the quenching of the coumarin emission and the
appearance of the FITC emission, indicating that the two
peptides interacted (Fig. 4b). Compared to anti-TMD5, anti-
TMD5 scrambled control peptide showed much less
quenching of TMD5-coumarin uorescence and weaker FRET
signal from FITC emission (Fig. S4†). These results agree well
with TMD5-coumarin uorescence dequenching experiments
and further support the specicity of anti-TMD5. By analysing
the quenching of coumarin-tagged TMD5 uorescence in theThis journal is © The Royal Society of Chemistry 2019
Fig. 4 Fluorescence dequenching and FRET assays: (a) anti-TMD5 disrupts LMP-1 TMD5 self-associations in the micelle and causes coumarin-
tagged TMD5 ﬂuorescence dequenching. Diﬀerent concentrations of unlabelled anti-TMD5 scrambled control or anti-TMD5 or NSC259242
were added into 50 nM of coumarin labelled TMD-5 solution (50 mM HEPES, pH ¼ 7.4) with 150 mM C14 betaine. Excitation, 360 nm; emission,
430 nm; (b) ﬂuorescence emission scans of coumarin-labelled TMD-5 (50 nM) in the presence of diﬀerent concentrations of FITC-tagged anti-
TMD-5 in 20mMHEPES, pH¼ 7.4, containing 1.0 mMC14 betaine at room temperature. lex was set at 415 nm to selectively excite the coumarin.
lex, excitation wavelength; (c) the quenching of coumarin labelled TMD-5 ﬂuorescence by anti-TMD-5 binding. A stoichiometry n¼ 0.53 0.02
and an apparent Kd of 67.8  7.5 nM were obtained.
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View Article OnlineC14 betaine micelle by FITC-tagged anti-TMD5, an apparent
dissociation constant (Kd) for the anti-TMD5 : TMD5 interac-
tion was determined to be 67.8  7.5 nM (Fig. 4c), and
a stoichiometry (n) of 0.53  0.02 was derived. The behaviour
of bilayers is diﬀerent from micelles, which are more
dynamic. The interactions of TMD5 with anti-TMD5 was also
investigated in bicelles composed of POPC and DHPC (q ¼
0.3). An apparent dissociation constant of 40.0  6.7 mM and
a stoichiometry of 0.44  0.03 were obtained for anti-
TMD5 : TMD5 interaction in bicelles (Fig. S5†). The results
show that anti-TMD5 has slightly stronger binding aﬃninty
towards TMD5 in bicelles than in micelles and consistently
indicates that two TMD5s interact with one anti-TMD5. To
investigate why two anti-TMD5 with one TMD5 (named as
heterotrimer_2 : 1) were not preferred for trimerization,
further molecular dynamics simulations were carried out. It
was observed that the variant Trp139s in anti-TMD5s fullled
the function of paddles to trap water molecules in the lumen;
four water molecules were captured in the lumen of the het-
erotrimer_2 : 1 (Fig. S6†). The occupancy of hydrogen bonds
formed between Asp150s of chain A and chain B (two anti-
TMD5s) was observed to be less than 1% in these simula-
tions, indicating that two anti-TMD5 and one TMD5 could not
form a stable trimer.
To cross validate the biophysical results, the anti-TMD5/
TMD5 interaction was investigated using a dominant-negative
ToxR assay (Fig. 5a) in bacterial membranes. ToxR is a bacte-
rial cell-based transcription reporter assay that detects trans-
membrane domain interactions within a cellular
membrane.27,39–42 Specically, a fusion protein consisting of
a transmembrane domain anked at the N-terminus by the
DNA binding domain of Vibrio cholerae ToxR protein and at the
C-terminus by maltose binding protein (MBP) is expressed in E.
coli strain FHK12, which has the ToxR target, the cholera toxin
(ctx) promoter, upstream of the b-galactosidase open reading
frame. When expressed in E. coli, this fusion protein willThis journal is © The Royal Society of Chemistry 2019localize and orient within the bacterial inner membrane. The
ToxR is only active in a dimeric form to cause lacZ transcription
with the product of b-galactosidase, and the activity of b-
galactosidase expressed in this system is proportional to the
strength of oligomerization of the transmembrane domains. In
the dominant-negative assay, the interaction of hetero-
complexes of TMDs can be observed by using an inactive
mutant ToxR fusion (ToxR*) with an active ToxR, and
comparing the b-galactosidase activity to the corresponding
homotypic interaction. As illustrated in Fig. 5b, integrin aIIb
and anti-aIIb27,43 were chosen as the model system to validate
the heterotypic interaction assay. The ToxR signal (Miller unit)
for the TMD5–ToxR construct was attenuated by co-expression
of anti-TMD5–ToxR*, but not by co-expression of anti-TMD5
scramble-ToxR* or poly-Leu-ToxR*. The results showed that
anti-TMD5 specically interacted with TMD5 while anti-TMD5
scramble and poly-Leu controls failed to signicantly interact
with TMD5.
TMD-5 trimerization is essential for LMP-1 signalling NF-
kB activation.20 In order to evaluate whether anti-TMD5 could
inhibit LMP-1 signalling, an NF-kB signalling assay was per-
formed. Naive B cells are the target of EBV infection in vivo,44,45
and thus an immortalized EBV positive B721 NF-kB reporter
cell line was selected for investigating the eﬀect of anti-TMD5
on LMP-1 signalling. As shown in Fig. 5c, anti-TMD5 inhibited
NF-kB activity in EBV positive B721 cells in a concentration
dependent manner, while anti-TMD5 scramble and
NSC259242, a TMD5 small molecule inhibitor with an IC50 of
29.6  6.6 mM in inhibiting B721 cell NF-kB activity as
a control,21 did not signicantly aﬀect the NF-kB activity at the
tested concentration range of 0–4 mM. The eﬀects of anti-
TMD5 on cell viability were also assessed in WST-1 assay.
Anti-TMD5 and anti-TMD5 scramble showed no apparent
cellular toxicity (Fig. S7†), which eliminates the possibility that
the observed NF-kB inhibition is due to the artifact of growth
inhibition.Chem. Sci., 2019, 10, 7584–7590 | 7587
Fig. 5 ToxR and NF-kB assays: (a) schematic representation of the ToxR assay used for testing LMP-1 TMD5 disruptors; (b) dominant-negative
ToxR assay. The anti-TMD5 reduced the TMD5Miller unit of the TMD5/TMD5 interaction by over 50%, whereas the controls (anti-TMD5 scramble
and poly-Leu) did not inhibit the TMD5Miller unit; (c) anti-TMD5 inhibited NF-kB activity in EBV positive B721 cells. Following 24 h treatment, the
constitutive LMP-1 NF-kB activity in B721 cells was determined by a Steady-Glo Luciferase Assay System. TheNF-kB activity of the untreated cells
was normalized as 1.
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View Article OnlineConclusions
Membrane proteins play vital roles in a tremendous number of
crucial biological functions. The transmembrane domains have
been deemed “undruggable” compared to their water soluble
counterparts. In this study, we have exemplied a strategy to
design a peptide to inhibit the homotrimeric self-association of
TMD5 by formation of an asymmetric heterotrimer by the
combination of computational and experimental methods. A
peptide inhibitor was rst designed in silico, and, the stability of
the trimer was investigated viamolecular dynamics simulations
when one or two of three TMD5s were replaced by the designed
anti-TMD5 peptide. A single anti-TMD5 peptide inhibitor eli-
cited strong ability to stabilize a heterotrimer assembly by
obscuring water molecules from the lumen and forming evenly
distributed intermolecular interactions. The TMD5 targeting
and inhibiting properties of anti-TMD5 were further cross
validated and characterized by biophysical, biochemical and7588 | Chem. Sci., 2019, 10, 7584–7590cellular assays. The results established the anti-TMD5 peptide
inhibitor as a promising starting point to elaborate drug
candidates for treatment of EBV infection. More broadly, this
study provides a proof of concept for the development of
peptides that exert a biological eﬀect by targeting membrane-
based protein–protein interactions to modulate the supramo-
lecular assembly of membrane proteins.Data availability
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study are available from the corresponding authors on request.Author contributions
Y. W., Y. P., and X. W. designed research; Y. W., Y. P., B. Z., and
X. Z. performed research; Y. W., Y. P., B. Z., X. Z., H. L., A. J. W.,This journal is © The Royal Society of Chemistry 2019
Edge Article Chemical Science
O
pe
n 
A
cc
es
s A
rti
cl
e.
 P
ub
lis
he
d 
on
 2
7 
Ju
ne
 2
01
9.
 D
ow
nl
oa
de
d 
on
 1
0/
7/
20
19
 1
1:
49
:0
2 
A
M
. 
 
Th
is 
ar
tic
le
 is
 li
ce
ns
ed
 u
nd
er
 a
 C
re
at
iv
e 
Co
m
m
on
s A
ttr
ib
ut
io
n-
N
on
Co
m
m
er
ci
al
 3
.0
 U
np
or
te
d 
Li
ce
nc
e.
View Article OnlineK. S. M. and X. W. analysed data; and Y. W., Y. P., B. Z., X. Z.,
H. L., A. J. W., K. S. M. and X. W. wrote the paper.
Conﬂicts of interest
There are no conicts to declare.
Acknowledgements
This work was supported by the National Natural Science
Foundation of China (21602216, 21877106, 21807098), the 100
Talents Program of Chinese Academy of Sciences, the Young
Talents Program of Chinese Academy of Agricultural Sciences,
the Central Public-Interest Scientic Institution Basal Research
Fund (NO. 1610342016013), the Natural Science Foundation of
Jilin Province (20180520059JH, 20180101021JC), the Open
Funds of State Key Laboratory of Oncology in South China
(HN2018-07) and the Royal Society-Newton Advanced Fellow-
ship (NA170152). Computing time was supported by the
Network and Computing Center, Changchun Institute of
Applied Chemistry, Chinese Academy of Sciences, the National
Supercomputer Center in Guangzhou and the Computing
Center of Jilin Province. The funders had no role in study
design, data collection and analysis, decision to publish, or
preparation of the manuscript.
Notes and references
1 M. Ahram, Z. I. Litou, R. Fang and G. Al-Tawallbeh, In Silico
Biol., 2006, 6, 379–386.
2 T. A. Stone and C. M. Deber, Biochim. Biophys. Acta,
Biomembr., 2017, 1859, 577–585.
3 D. M. Hershey, X. F. Ren, R. A. Melnyk, P. J. Browne,
E. Ozyamak, S. R. Jones, M. C. Y. Chang, J. H. Hurley and
A. Komeili, PLoS Biol., 2016, 14, e1002402.
4 R. A. Brown, V. Diemer, S. J. Webb and J. Clayden, Nat.
Chem., 2013, 5, 853–860.
5 C. M. Grison, J. A. Miles, S. Robin, A. J. Wilson and
D. J. Aitken, Angew. Chem., Int. Ed. Engl., 2016, 55, 11096–
11100.
6 A. J. Wilson, Chem. Soc. Rev., 2009, 38, 3289–3300.
7 H. Yin, Angew. Chem., Int. Ed. Engl., 2008, 47, 2744–2752.
8 T. X. Zhao, A. J. Martinko, V. H. Le, J. Zhao and H. Yin, Curr.
Pharm. Des., 2010, 16, 1055–1062.
9 H. M. Berman, J. Westbrook, Z. Feng, G. Gilliland, T. N. Bhat,
H. Weissig, I. N. Shindyalov and P. E. Bourne, Nucleic Acids
Res., 2000, 28, 235–242.
10 S. H. White, Protein Sci., 2004, 13, 1948–1949.
11 M. De Poli, W. Zawodny, O. Quinonero, M. Lorch, S. J. Webb
and J. Clayden, Science, 2016, 352, 575–580.
12 G. Brady, G. J. MacArthur and P. J. Farrell, J. Clin. Pathol.,
2007, 60, 1397–1402.
13 G. Henle, W. Henle and V. Diehl, Proc. Natl. Acad. Sci. U. S. A.,
1968, 59, 94–101.
14 Z. M. Zheng, Int. J. Biol. Sci., 2010, 6, 730–755.
15 K. J. Flavell and P. G. Murray,Mol. Pathol., 2000, 53, 262–269.
16 B. Sugden, Cell, 1989, 57, 5–7.This journal is © The Royal Society of Chemistry 201917 U. Dirmeier, B. Neuhierl, E. Kilger, G. Reisbach,
M. L. Sandberg and W. Hammerschmidt, Cancer Res.,
2003, 63, 2982–2989.
18 K. M. Kaye, K. M. Izumi and E. Kieﬀ, Proc. Natl. Acad. Sci. U.
S. A., 1993, 90, 9150–9154.
19 D. Wang, D. Liebowitz and E. Kieﬀ, Cell, 1985, 43, 831–840.
20 D. W. Sammond, C. Joce, R. Takeshita, S. E. McQuate,
N. Ghosh, J. M. Martin and H. Yin, Biopolymers, 2011, 95,
772–784.
21 X. H. Wang, J. P. Saludes, T. X. Zhao, A. Csakai, Z. Fiorini,
S. A. Chavez, J. Li, G. I. Lee, K. Varga and H. Yin, Biochim.
Biophys. Acta, Biomembr., 2012, 1818, 2282–2289.
22 X. H. Wang, Z. Fiorini, C. Smith, Y. N. Zhang, J. Li,
L. R. Watkins and H. Yin, PLoS One, 2012, 7, e47703.
23 X. Zeng, P. Wu, C. Yao, J. Liang, S. Zhang and H. Yin,
Biochemistry, 2017, 56, 2076–2085.
24 A. Fink, E. M. Reuven, C. J. Arnusch, L. Shmuel-Galia,
N. Antonovsky and Y. Shai, J. Immunol., 2013, 190, 6410–
6422.
25 L. Shmuel-Galia, T. Aychek, A. Fink, Z. Porat, B. Zarmi,
B. Bernshtein, O. Brenner, S. Jung and Y. Shai, EMBO J.,
2016, 35, 685–698.
26 A. Bennasroune, M. Fickova, A. Gardin, S. Dirrig-Grosch,
D. Aunis, G. Cremel and P. Hubert, Mol. Biol. Cell, 2004,
15, 3464–3474.
27 H. Yin, J. S. Slusky, B. W. Berger, R. S. Walters, G. Vilaire,
R. I. Litvinov, J. D. Lear, G. A. Caputo, J. S. Bennett and
W. F. DeGrado, Science, 2007, 315, 1817–1822.
28 S. Q. Zhang, H. Huang, J. J. Yang, H. T. Kratochvil,
M. Lolicato, Y. X. Liu, X. K. Shu, L. J. Liu and
W. F. DeGrado, Nat. Chem. Biol., 2018, 14, 870–875.
29 F. Findeisen, M. Campiglio, H. Jo, F. Abderemane-Ali,
C. H. Rumpf, L. Pope, N. D. Rossen, B. E. Flucher,
W. F. DeGrado and D. L. Minor, ACS Chem. Neurosci., 2017,
8, 1313–1326.
30 S. P. Ho and W. F. Degrado, J. Am. Chem. Soc., 1987, 109,
6751–6758.
31 B. Kuhlman, G. Dantas, G. C. Ireton, G. Varani,
B. L. Stoddard and D. Baker, Science, 2003, 302, 1364–1368.
32 A. Leaver-Fay, M. Tyka, S. M. Lewis, O. F. Lange,
J. Thompson, R. Jacak, K. Kaufman, P. D. Renfrew,
C. A. Smith, W. Sheﬄer, I. W. Davis, S. Cooper, A. Treuille,
D. J. Mandell, F. Richter, Y. E. Ban, S. J. Fleishman,
J. E. Corn, D. E. Kim, S. Lyskov, M. Berrondo, S. Mentzer,
Z. Popovic, J. J. Havranek, J. Karanicolas, R. Das, J. Meiler,
T. Kortemme, J. J. Gray, B. Kuhlman, D. Baker and
P. Bradley, Methods Enzymol., 2011, 487, 545–574.
33 N. Koga, R. Tatsumi-Koga, G. Liu, R. Xiao, T. B. Acton,
G. T. Montelione and D. Baker, Nature, 2012, 491, 222–227.
34 V. D. Sood and D. Baker, J. Mol. Biol., 2006, 357, 917–927.
35 R. Jacak, A. Leaver-Fay and B. Kuhlman, Proteins, 2012, 80,
825–838.
36 B. Kuhlman and D. Baker, Proc. Natl. Acad. Sci. U. S. A., 2000,
97, 10383–10388.
37 C. A. Rohl, C. E. M. Strauss, K. M. S. Misura and D. Baker,
Methods Enzymol., 2004, 383, 66–93.Chem. Sci., 2019, 10, 7584–7590 | 7589
Chemical Science Edge Article
O
pe
n 
A
cc
es
s A
rti
cl
e.
 P
ub
lis
he
d 
on
 2
7 
Ju
ne
 2
01
9.
 D
ow
nl
oa
de
d 
on
 1
0/
7/
20
19
 1
1:
49
:0
2 
A
M
. 
 
Th
is 
ar
tic
le
 is
 li
ce
ns
ed
 u
nd
er
 a
 C
re
at
iv
e 
Co
m
m
on
s A
ttr
ib
ut
io
n-
N
on
Co
m
m
er
ci
al
 3
.0
 U
np
or
te
d 
Li
ce
nc
e.
View Article Online38 A. Piai, J. Dev, Q. Fu and J. J. Chou, J. Am. Chem. Soc., 2017,
139, 18432–18435.
39 E. Lindner and D. Langosch, Proteins, 2006, 65, 803–807.
40 D. Langosch, B. Brosig, H. Kolmar and H. J. Fritz, J. Mol.
Biol., 1996, 263, 525–530.
41 W. P. Russ and D. M. Engelman, Proc. Natl. Acad. Sci. U. S. A.,
1999, 96, 863–868.7590 | Chem. Sci., 2019, 10, 7584–759042 C. Joce, A. Wiener and H. Yin, J. Visualized Exp., 2011, 51,
e2721.
43 S. J. Shandler, I. V. Korendovych, D. T. Moore, K. B. Smith-
Dupont, C. N. Streu, R. I. Litvinov, P. C. Billings, F. Gai,
J. S. Bennett and W. F. DeGrado, J. Am. Chem. Soc., 2011,
133, 12378–12381.
44 D. A. Thorley-Lawson, Nat. Rev. Immunol., 2001, 1, 75–82.
45 R. Kuppers, Nat. Rev. Immunol., 2003, 3, 801–812.This journal is © The Royal Society of Chemistry 2019
